JP7763450B2 - 免疫療法に関するオルガノイドならびにそれを調製および使用する方法 - Google Patents
免疫療法に関するオルガノイドならびにそれを調製および使用する方法Info
- Publication number
- JP7763450B2 JP7763450B2 JP2020540738A JP2020540738A JP7763450B2 JP 7763450 B2 JP7763450 B2 JP 7763450B2 JP 2020540738 A JP2020540738 A JP 2020540738A JP 2020540738 A JP2020540738 A JP 2020540738A JP 7763450 B2 JP7763450 B2 JP 7763450B2
- Authority
- JP
- Japan
- Prior art keywords
- cells
- tumor
- organoids
- immune
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4244—Enzymes
- A61K40/4245—Tyrosinase or tyrosinase related proteinases [TRP-1 or TRP-2]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4271—Melanoma antigens
- A61K40/4272—Melan-A/MART
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4271—Melanoma antigens
- A61K40/4273—Glycoprotein 100 [Gp100]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0693—Tumour cells; Cancer cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0697—Artificial constructs associating cells of different lineages, e.g. tissue equivalents
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
- G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
-
- G—PHYSICS
- G06—COMPUTING OR CALCULATING; COUNTING
- G06V—IMAGE OR VIDEO RECOGNITION OR UNDERSTANDING
- G06V20/00—Scenes; Scene-specific elements
- G06V20/60—Type of objects
- G06V20/69—Microscopic objects, e.g. biological cells or cellular parts
- G06V20/698—Matching; Classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2513/00—3D culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2521/00—Culture process characterised by the use of hydrostatic pressure, flow or shear forces
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Toxicology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Multimedia (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023118838A JP2023139153A (ja) | 2018-02-02 | 2023-07-21 | 免疫療法に関するオルガノイドならびにそれを調製および使用する方法 |
| JP2025125610A JP2025172735A (ja) | 2018-02-02 | 2025-07-28 | 免疫療法に関するオルガノイドならびにそれを調製および使用する方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862625628P | 2018-02-02 | 2018-02-02 | |
| US62/625,628 | 2018-02-02 | ||
| PCT/US2019/016236 WO2019152767A1 (en) | 2018-02-02 | 2019-02-01 | Organoids related to immunotherapy and methods of preparing and using the same |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023118838A Division JP2023139153A (ja) | 2018-02-02 | 2023-07-21 | 免疫療法に関するオルガノイドならびにそれを調製および使用する方法 |
| JP2025125610A Division JP2025172735A (ja) | 2018-02-02 | 2025-07-28 | 免疫療法に関するオルガノイドならびにそれを調製および使用する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021511790A JP2021511790A (ja) | 2021-05-13 |
| JP2021511790A5 JP2021511790A5 (cg-RX-API-DMAC7.html) | 2022-01-21 |
| JP7763450B2 true JP7763450B2 (ja) | 2025-11-04 |
Family
ID=67478724
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020540738A Active JP7763450B2 (ja) | 2018-02-02 | 2019-02-01 | 免疫療法に関するオルガノイドならびにそれを調製および使用する方法 |
| JP2023118838A Pending JP2023139153A (ja) | 2018-02-02 | 2023-07-21 | 免疫療法に関するオルガノイドならびにそれを調製および使用する方法 |
| JP2025125610A Pending JP2025172735A (ja) | 2018-02-02 | 2025-07-28 | 免疫療法に関するオルガノイドならびにそれを調製および使用する方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023118838A Pending JP2023139153A (ja) | 2018-02-02 | 2023-07-21 | 免疫療法に関するオルガノイドならびにそれを調製および使用する方法 |
| JP2025125610A Pending JP2025172735A (ja) | 2018-02-02 | 2025-07-28 | 免疫療法に関するオルガノイドならびにそれを調製および使用する方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US12038432B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3746785A4 (cg-RX-API-DMAC7.html) |
| JP (3) | JP7763450B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102820005B1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019215096B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3089127A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019152767A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3356512B1 (en) | 2015-10-02 | 2021-03-31 | Wake Forest University Health Sciences, Inc. | Methods and apparatus for modeling cancer metastasis in vitro |
| CA3287905A1 (en) | 2016-10-14 | 2025-11-29 | Wake Forest University Health Sciences | Compositions, cell constructs, and methods of making and using the same |
| WO2018081425A1 (en) | 2016-10-26 | 2018-05-03 | Wake Forest University Health Sciences | Hydrogen-bonding compounds, compositions comprising the same, and methods of preparing and using the same |
| US11629329B2 (en) | 2017-10-11 | 2023-04-18 | Wake Forest University Health Sciences | Bioink compositions and methods of preparing and using the same |
| JP7763450B2 (ja) | 2018-02-02 | 2025-11-04 | ウェイク・フォレスト・ユニバーシティ・ヘルス・サイエンシーズ | 免疫療法に関するオルガノイドならびにそれを調製および使用する方法 |
| US11993785B2 (en) | 2018-08-07 | 2024-05-28 | Wake Forest University Health Sciences | Immersion deposition methods and compositions for use in the same |
| US11213608B2 (en) | 2018-08-14 | 2022-01-04 | Wake Forest University Health Sciences | Compositions including gelatin nanoparticles and methods of use thereof |
| EP4048809B1 (en) | 2019-10-22 | 2026-05-27 | Tempus AI, Inc. | Systems and methods for predicting therapeutic sensitivity |
| JP7744340B2 (ja) | 2019-12-05 | 2025-09-25 | テンパス・エーアイ・インコーポレイテッド | ハイスループット薬物スクリーニングのためのシステムおよび方法 |
| US11561178B2 (en) | 2020-04-20 | 2023-01-24 | Tempus Labs, Inc. | Artificial fluorescent image systems and methods |
| CN116615654A (zh) * | 2020-11-24 | 2023-08-18 | 杜克大学 | 基于液滴类器官的免疫肿瘤学分析及其使用方法 |
| US20240110155A1 (en) * | 2020-12-17 | 2024-04-04 | Genome Biologics Ug | A dual cardiac-blood model system for disease modelling and drug screening |
| WO2022154754A1 (en) * | 2021-01-15 | 2022-07-21 | Nanyang Technological University | Core-shell microspheres |
| EP4060552B1 (en) * | 2021-03-15 | 2025-02-26 | Universiteit Antwerpen | Label-free analysis of brightfield microscope images |
| JP2024534463A (ja) * | 2021-09-15 | 2024-09-20 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | オルガノイドを使用して腫瘍反応性免疫集団を増幅する方法 |
| KR102511632B1 (ko) * | 2022-07-26 | 2023-03-20 | 오가노이드사이언스 주식회사 | 암 오가노이드 및 til 포함 종양 미세환경을 이용한 항암제 효능 평가 방법 |
| KR102527906B1 (ko) * | 2022-07-29 | 2023-05-02 | 오가노이드사이언스 주식회사 | 수지상 세포의 약물 효능평가 용도 |
| KR102511633B1 (ko) * | 2022-08-09 | 2023-03-20 | 오가노이드사이언스 주식회사 | M1 마크로파지 및 m2 마크로파지 혼합물을 이용한 항암제 효능 평가 방법 |
| KR102527911B1 (ko) * | 2022-08-02 | 2023-05-02 | 오가노이드사이언스 주식회사 | 조절 t 세포의 약물 스크리닝 용도 |
| US20240219373A1 (en) * | 2021-09-17 | 2024-07-04 | Organoidsciences Ltd. | Method for evaluating efficacy of anticancer drug or screening anticancer drug |
| CN115521898A (zh) * | 2021-11-04 | 2022-12-27 | 上海万何圆生物科技有限公司 | 肝癌类器官与nk细胞共培养的免疫细胞治疗方法及应用 |
| CN115537395A (zh) * | 2021-11-04 | 2022-12-30 | 上海万何圆生物科技有限公司 | 一种肝癌类器官与TILs细胞共培养的治疗方法及其应用 |
| CN115521912A (zh) * | 2021-11-04 | 2022-12-27 | 上海万何圆生物科技有限公司 | 一种以类器官与t细胞共培养的免疫细胞治疗方法及应用 |
| KR102818207B1 (ko) * | 2022-02-10 | 2025-06-12 | 가톨릭대학교 산학협력단 | 환자 유래 뇌수막종 오가노이드 및 이의 제조 방법 |
| TWI825620B (zh) * | 2022-03-14 | 2023-12-11 | 國立清華大學 | 細胞分選方法 |
| EP4555071A4 (en) * | 2022-07-15 | 2026-07-08 | Parallel Bio | COMPOSITIONS AND METHODS FOR PRODUCING IMMUNE ORGANOIDS THAT GENERATE ANTIBODIES |
| EP4649134A1 (en) * | 2023-01-10 | 2025-11-19 | Georgia Tech Research Corporation | In vitro platform for cell sorting |
| KR102952410B1 (ko) * | 2023-01-20 | 2026-04-14 | 에스지바이오사이언스 주식회사 | 육종 튜머로이드 제조 방법 및 그의 용도 |
| WO2025070382A1 (ja) * | 2023-09-25 | 2025-04-03 | 武田薬品工業株式会社 | アッセイ方法 |
| WO2025085577A1 (en) * | 2023-10-17 | 2025-04-24 | NetNoids Rx Laboratories, LLC | Compositions and methods for accelerating development of cancer therapeutics |
| CN117511880B (zh) * | 2024-01-08 | 2024-04-19 | 北京大橡科技有限公司 | 肿瘤体外原位模型的构建方法、培养基及体外应用 |
| CN118006555B (zh) * | 2024-04-10 | 2024-06-25 | 北京市肿瘤防治研究所 | 一种黑色素瘤类器官培养基及其用途 |
| EP4759925A1 (en) * | 2024-12-12 | 2026-06-17 | Eberhard Karls Universität Tübingen (Medizinische Fakultät) | Method for generating a tumor assembloid |
| CN119851750A (zh) * | 2025-03-19 | 2025-04-18 | 华中科技大学同济医学院附属同济医院 | 肝脏类器官的药物筛选和疾病模型构建的方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013519360A (ja) | 2010-02-11 | 2013-05-30 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 3dadccnkfacsアッセイ |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4734372A (en) | 1983-02-04 | 1988-03-29 | Brown University Research Foundation | Cell culturing methods and apparatus |
| PT914043E (pt) | 1996-04-03 | 2004-02-27 | Rogosin Inst | Perolas de agarose-colagenio implantaveis contendo celulas que produzem um produto biologico difusivel e suas utilizacoes |
| US6224912B1 (en) * | 1996-04-03 | 2001-05-01 | The Rogo Institute | Cancer-cell proliferation-suppressing material produced by cancer cells restricted by entrapment |
| ATE306559T1 (de) | 1998-02-18 | 2005-10-15 | Herman H Vandenburgh | Verfahren zum screenen von verbindungen mit bioaktivität in organgeweben |
| FR2791505B1 (fr) | 1999-03-25 | 2001-06-08 | Inside Technologies | Decodeur bpsk synchrone |
| AU2002356043A1 (en) | 2001-08-14 | 2003-03-03 | Washington University In St. Louis | Systems and methods for screening pharmaceutical chemicals |
| NZ539713A (en) | 2002-10-11 | 2008-07-31 | Novocell Inc | Implantation of encapsulated biological materials for treating diseases |
| AU2004292180A1 (en) | 2003-11-13 | 2005-06-02 | Genentech, Inc. | Screening assays and methods of tumor treatment |
| US8298824B2 (en) * | 2004-04-28 | 2012-10-30 | Sanofi Pasteur Vaxdesign Corporation | Methods of evaluating a test agent in a diseased cell model |
| US20060141620A1 (en) | 2004-11-15 | 2006-06-29 | The Regents Of The University Of Michigan | System and method for forming a cardiac tissue construct |
| WO2007070660A2 (en) | 2005-12-13 | 2007-06-21 | President And Fellows Of Harvard College | Scaffolds for cell transplantation |
| EP1988769A2 (en) | 2006-02-10 | 2008-11-12 | Tengion, Inc. | Bioreactor for organ reconstruction and augmentation |
| JP4987885B2 (ja) | 2006-03-09 | 2012-07-25 | エージェンシー フォー サイエンス,テクノロジー アンド リサーチ | 小滴中で反応を行うための装置及びその使用方法 |
| JP5024777B2 (ja) | 2006-03-14 | 2012-09-12 | 独立行政法人農業・食品産業技術総合研究機構 | 細胞動態の観察装置 |
| JP2008054521A (ja) | 2006-08-29 | 2008-03-13 | Canon Inc | 細胞培養処理装置及び細胞培養処理方法 |
| EP2069472A4 (en) | 2006-10-05 | 2012-06-20 | Nanopoint Inc | SYSTEMS AND METHODS OF HANDLING AN ACTIVE MICROFLUIDIC CELL |
| FR2917293B1 (fr) | 2007-06-13 | 2010-11-26 | Olivier Paul Christian Schussler | Support collagenique modifie par greffage covalent de molecules d'adhesion : procedes et applications pour l'ingenierie de tissu contractile, la therapie cellulaire en thoracique et cardiovasculaire |
| US20090076584A1 (en) | 2007-09-19 | 2009-03-19 | Xtent, Inc. | Apparatus and methods for deployment of multiple custom-length prostheses |
| CA2727003C (en) | 2008-06-04 | 2018-09-18 | Uwe Marx | Organ-on-a-chip-device |
| IT1392820B1 (it) | 2008-08-06 | 2012-03-23 | Dominici | Dispositivo per la coltura di cellule |
| GB0815428D0 (en) | 2008-08-22 | 2008-10-01 | Capsant Neurotechnologies S A | Method |
| WO2011014674A2 (en) | 2009-07-29 | 2011-02-03 | Cornell University | Microfluidic device for pharmacokinetic-pharmacodynamic study of drugs and uses thereof |
| EP2521587B1 (en) | 2010-01-08 | 2020-04-08 | Wake Forest University Health Sciences | Delivery system |
| US20130172985A1 (en) | 2010-01-15 | 2013-07-04 | University Of Utah Research Foundation | Crosslinked hydrogels and methods of making and using thereof |
| SG187214A1 (en) | 2010-08-06 | 2013-02-28 | Univ Berlin Tech | Circulation system |
| US20120089238A1 (en) | 2010-10-06 | 2012-04-12 | Hyun-Wook Kang | Integrated organ and tissue printing methods, system and apparatus |
| EP2755598B1 (en) | 2011-09-16 | 2019-03-06 | Wake Forest University Health Sciences | Fabrication of gelatin hydrogel sheet for the transplantation of corneal endothelium |
| WO2013086502A1 (en) | 2011-12-09 | 2013-06-13 | President And Fellows Of Harvard College | Organ chips and uses thereof |
| US9725687B2 (en) | 2011-12-09 | 2017-08-08 | President And Fellows Of Harvard College | Integrated human organ-on-chip microphysiological systems |
| WO2013086512A2 (en) | 2011-12-09 | 2013-06-13 | President And Fellows Of Harvard College | Muscle chips and methods of use thereof |
| CN113699105A (zh) | 2011-12-23 | 2021-11-26 | 人类起源公司 | 包含脱细胞并再群体化的胎盘血管支架的类器官 |
| JP2014033626A (ja) | 2012-08-08 | 2014-02-24 | Juntendo | ヒト癌上皮細胞の遠隔転移のモデルマウス作出方法 |
| WO2014040026A2 (en) | 2012-09-10 | 2014-03-13 | Wake Forest University Health Sciences | Amniotic membrane and its use in wound healing and tissue engineering constructs |
| EP2712918B1 (en) | 2012-09-28 | 2014-11-12 | TissUse GmbH | Multi-organ-chip with improved life time and homoeostasis |
| US20140178988A1 (en) | 2012-10-08 | 2014-06-26 | Biotime, Inc. | Differentiated Progeny of Clonal Progenitor Cell Lines |
| US10012640B2 (en) | 2013-02-14 | 2018-07-03 | Cfd Research Corporation | Cell culture device with an array of microfluidic networks |
| EP2971057A4 (en) | 2013-03-15 | 2016-11-02 | Kiyatec Inc | BIOREACTOR SYSTEM |
| US9460931B2 (en) | 2013-09-17 | 2016-10-04 | Sandisk Technologies Llc | High aspect ratio memory hole channel contact formation |
| US9587221B2 (en) | 2013-11-11 | 2017-03-07 | Auburn University | Encapsulation and cardiac differentiation of hiPSCs in 3D PEG-fibrinogen hydrogels |
| KR20160106108A (ko) | 2014-01-22 | 2016-09-09 | 제트프리딕타, 인코포레이티드 | 치료제를 평가하고 전이 능력을 예측하기 위해 침습성 및 전이성 세포를 분리하기 위한 방법 및 장치 |
| JP6284147B2 (ja) | 2014-03-07 | 2018-02-28 | 国立研究開発法人産業技術総合研究所 | 乳癌の骨髄高転移性マウス乳癌細胞株の樹立方法 |
| KR20170013865A (ko) | 2014-04-04 | 2017-02-07 | 오가노보, 인크. | 조작된 3차원 유방 조직, 지방조직, 및 종양 질병 모델 |
| ES2907553T3 (es) * | 2014-05-26 | 2022-04-25 | Univ Basel | Cultivo o expansión in vitro de tejido humano o animal |
| US10634665B2 (en) | 2014-09-24 | 2020-04-28 | Triad National Security, Llc | Bio-assessment device and method of making the device |
| CA3191977C (en) | 2014-10-24 | 2026-05-12 | Wake Forest University Health Sciences | Tissue-mimicking hydrogel compositions for biofabrication |
| WO2016081554A1 (en) | 2014-11-18 | 2016-05-26 | Neostem Oncology, Llc | Immunogenic compositions prepared from tumor cells derived from peripheral blood and originating from a solid tumor and their use |
| US20180355298A1 (en) | 2014-12-15 | 2018-12-13 | The Regents Of The University Of California | Multi-organ cell culture system and methods of use thereof |
| EP3356517A4 (en) | 2015-10-02 | 2019-04-03 | Wake Forest University Health Sciences | SPONTANEOUS HERB ORGANOID CONSTRUCTS AND INTEGRATED BODY ON CHIP DEVICE WITH IT |
| EP3356512B1 (en) * | 2015-10-02 | 2021-03-31 | Wake Forest University Health Sciences, Inc. | Methods and apparatus for modeling cancer metastasis in vitro |
| JP6873985B2 (ja) | 2015-10-15 | 2021-05-19 | ウェイク・フォレスト・ユニヴァーシティ・ヘルス・サイエンシズ | インビトロで肝臓構築物を産生する方法およびその使用 |
| US10993433B2 (en) | 2015-10-15 | 2021-05-04 | Wake Forest University Health Sciences | Method of producing in vitro testicular constructs and uses thereof |
| JP7011828B2 (ja) | 2015-10-16 | 2022-01-27 | ウェイク・フォレスト・ユニヴァーシティ・ヘルス・サイエンシズ | 多層気道オルガノイドならびにそれを調製および使用する方法 |
| CA3205061C (en) * | 2016-03-30 | 2024-02-13 | EMULATE, Inc. | Methods of determining tumor marker expression in human tumor cells |
| ES3056995T3 (en) * | 2016-04-13 | 2026-02-25 | Vivia Biotech Sl | Ex vivo bite-activated t cells |
| EP3936610A1 (en) | 2016-05-25 | 2022-01-12 | Salk Institute for Biological Studies | Compositions and methods for organoid generation and disease modeling |
| US10766970B2 (en) | 2016-07-01 | 2020-09-08 | Wake Forest University Health Sciences | Modified carbohydrates, compositions comprising the same, and methods of making and using the same |
| US20180000743A1 (en) | 2016-07-01 | 2018-01-04 | Wake Forest University | Modified Alginate Hydrogels for Therapeutic Agents, their Preparation and Methods Thereof |
| WO2018013589A1 (en) | 2016-07-12 | 2018-01-18 | Flagship Pioneering, Inc. | Methods and compositions for thymic transplantation |
| KR20230084308A (ko) | 2016-08-03 | 2023-06-12 | 웨이크 포리스트 유니버시티 헬스 사이언시즈 | 암 모델링 플랫폼 및 그를 사용하는 방법 |
| EP4253956A3 (en) | 2016-10-14 | 2023-12-06 | Wake Forest University Health Sciences | Multi-organ "body on a chip" apparatus utilizing a common media |
| CA3287905A1 (en) | 2016-10-14 | 2025-11-29 | Wake Forest University Health Sciences | Compositions, cell constructs, and methods of making and using the same |
| WO2018081425A1 (en) | 2016-10-26 | 2018-05-03 | Wake Forest University Health Sciences | Hydrogen-bonding compounds, compositions comprising the same, and methods of preparing and using the same |
| US11180735B2 (en) * | 2016-10-28 | 2021-11-23 | The Board Of Trustees Of The Leland Stanford Junior University | Methods to preserve tumor-stromal interactions in culture and therapeutic predictive applications thereof |
| US11826757B2 (en) | 2017-08-02 | 2023-11-28 | Wake Forest University Health Sciences | Niches-on-a-chip |
| US11629329B2 (en) | 2017-10-11 | 2023-04-18 | Wake Forest University Health Sciences | Bioink compositions and methods of preparing and using the same |
| JP7763450B2 (ja) | 2018-02-02 | 2025-11-04 | ウェイク・フォレスト・ユニバーシティ・ヘルス・サイエンシーズ | 免疫療法に関するオルガノイドならびにそれを調製および使用する方法 |
| US11993785B2 (en) | 2018-08-07 | 2024-05-28 | Wake Forest University Health Sciences | Immersion deposition methods and compositions for use in the same |
| US11213608B2 (en) | 2018-08-14 | 2022-01-04 | Wake Forest University Health Sciences | Compositions including gelatin nanoparticles and methods of use thereof |
| WO2020132133A1 (en) | 2018-12-18 | 2020-06-25 | Beth Israel Deaconess Medical Center, Inc. | Generation of organoid-primed t (opt) cells with memory phenotype |
-
2019
- 2019-02-01 JP JP2020540738A patent/JP7763450B2/ja active Active
- 2019-02-01 EP EP19746913.3A patent/EP3746785A4/en active Pending
- 2019-02-01 WO PCT/US2019/016236 patent/WO2019152767A1/en not_active Ceased
- 2019-02-01 US US16/966,406 patent/US12038432B2/en active Active
- 2019-02-01 CA CA3089127A patent/CA3089127A1/en active Pending
- 2019-02-01 AU AU2019215096A patent/AU2019215096B2/en active Active
- 2019-02-01 KR KR1020207023638A patent/KR102820005B1/ko active Active
-
2023
- 2023-07-21 JP JP2023118838A patent/JP2023139153A/ja active Pending
-
2024
- 2024-06-03 US US18/731,629 patent/US20240329034A1/en active Pending
-
2025
- 2025-07-28 JP JP2025125610A patent/JP2025172735A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013519360A (ja) | 2010-02-11 | 2013-05-30 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 3dadccnkfacsアッセイ |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2019215096B2 (en) | 2025-04-10 |
| AU2019215096A1 (en) | 2020-08-06 |
| WO2019152767A1 (en) | 2019-08-08 |
| US20240329034A1 (en) | 2024-10-03 |
| JP2025172735A (ja) | 2025-11-26 |
| EP3746785A4 (en) | 2022-05-11 |
| US12038432B2 (en) | 2024-07-16 |
| JP2021511790A (ja) | 2021-05-13 |
| JP2023139153A (ja) | 2023-10-03 |
| KR20200116944A (ko) | 2020-10-13 |
| KR102820005B1 (ko) | 2025-06-12 |
| CA3089127A1 (en) | 2019-08-08 |
| EP3746785A1 (en) | 2020-12-09 |
| US20200363402A1 (en) | 2020-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240329034A1 (en) | Organoids related to immunotherapy and methods of preparing and using the same | |
| AU2024204173B2 (en) | Compositions, cell constructs, and methods of making and using the same | |
| US20240192194A1 (en) | Cancer modeling platforms and methods of using the same | |
| Miserocchi et al. | Management and potentialities of primary cancer cultures in preclinical and translational studies | |
| US20240344005A1 (en) | Devices, systems and methods for inhibiting invasion and metastases of cancer | |
| CN114410466A (zh) | 用于个性化癌症治疗的精确药物筛选 | |
| CN120958119A (zh) | 将组分递送到微器官球的方法 | |
| Greissinger | Advancing T Cell Mediated Therapy Using 3D Tumor Organoids and Microfluidics | |
| CN119677867A (zh) | 用于使用微有机球测试肝细胞毒性的方法和装置 | |
| KR20250154508A (ko) | 미세유기구에서의 세포 표지 및 주석 | |
| HK40074891A (en) | Precision drug screening for personalized cancer therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220113 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220113 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221130 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20221130 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230215 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230327 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230721 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230808 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20230831 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20231013 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250728 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20251015 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7763450 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |